scispace - formally typeset
Open AccessJournal ArticleDOI

Minimal functional driver gene heterogeneity among untreated metastases

Reads0
Chats0
TLDR
Within individual patients, a large majority of driver gene mutations are common to all metastases, and a mathematical model of tumor evolution and metastasis formation provides an explanation for the observed driver gene homogeneity.
Abstract
Metastases are responsible for the majority of cancer-related deaths. Although genomic heterogeneity within primary tumors is associated with relapse, heterogeneity among treatment-naive metastases has not been comprehensively assessed. We analyzed sequencing data for 76 untreated metastases from 20 patients and inferred cancer phylogenies for breast, colorectal, endometrial, gastric, lung, melanoma, pancreatic, and prostate cancers. We found that within individual patients, a large majority of driver gene mutations are common to all metastases. Further analysis revealed that the driver gene mutations that were not shared by all metastases are unlikely to have functional consequences. A mathematical model of tumor evolution and metastasis formation provides an explanation for the observed driver gene homogeneity. Thus, single biopsies capture most of the functionally important mutations in metastases and therefore provide essential information for therapeutic decision-making.

read more

Citations
More filters

SF-010-4 Distant metastasis occurs late during the genetic evolution of pancreatic cancer

TL;DR: A quantitative analysis of the timing of the genetic evolution of pancreatic cancer was performed, indicating at least a decade between the occurrence of the initiating mutation and the birth of the parental, non-metastatic founder cell.
Journal ArticleDOI

Pan-cancer whole-genome analyses of metastatic solid tumours

TL;DR: The largest, to the authors' knowledge, pan-cancer study of metastatic solid tumour genomes, including whole-genome sequencing data for 2,520 pairs of tumour and normal tissue pairs, analysed at median depths of 106× and 38×, respectively, and surveying more than 70 million somatic variants is described.
Journal ArticleDOI

Tumour evolution in hepatocellular carcinoma.

TL;DR: The molecular heterogeneity of hepatocellular carcinoma, the intrinsic and extrinsic factors that stimulate tumour evolution and how this information can be leveraged to improve the clinical management of patients with this disease are discussed.
Journal ArticleDOI

Resolving genetic heterogeneity in cancer.

TL;DR: An overview of the theoretical models of tumour evolution is provided and what to consider when inferring evolutionary dynamics from genomic data is discussed.
Journal ArticleDOI

Context is everything: aneuploidy in cancer

TL;DR: The context dependency of aneuploidy in cancer is explained and its clinical potential is discussed, which may have clinical relevance as a prognostic marker and as a potential therapeutic target.
References
More filters
Journal ArticleDOI

A genetic model for colorectal tumorigenesis

TL;DR: A model for the genetic basis of colorectal neoplasia that includes the following salient features is presented, which may be applicable to other common epithelial neoplasms, in which tumors of varying stage are more difficult to study.
Journal ArticleDOI

A method and server for predicting damaging missense mutations.

TL;DR: A new method and the corresponding software tool, PolyPhen-2, which is different from the early tool polyPhen1 in the set of predictive features, alignment pipeline, and the method of classification is presented and performance, as presented by its receiver operating characteristic curves, was consistently superior.
Journal ArticleDOI

Cancer Genome Landscapes

TL;DR: This work has revealed the genomic landscapes of common forms of human cancer, which consists of a small number of “mountains” (genes altered in a high percentage of tumors) and a much larger number of "hills" (Genes altered infrequently).
Journal ArticleDOI

The clonal evolution of tumor cell populations

TL;DR: Each patient's cancer may require individual specific therapy, and even this may be thwarted by emergence of a genetically variant subline resistant to the treatment, which should be directed toward understanding and controlling the evolutionary process in tumors before it reaches the late stage usually seen in clinical cancer.
Related Papers (5)

Tracking the Evolution of Non–Small-Cell Lung Cancer

Mariam Jamal-Hanjani, +82 more